- Global Pharma News & Resources

Benign Prostatic Hyperplasia Therapeutics Market to Surpass $20,096.68 Mn by 2025 at a Hyper CAGR of 8.1%

The increase in the elderly male population is a major factor driving the demand for benign prostatic hyperplasia for the treatment of benign prostatic hyperplasia. This enlargement of the prostate is characterized by partial or complete blockage of the urinary tract and ultimately impedes normal urine flow. In addition, increased awareness of prostate cancer and other urological diseases is expected to increase the demand for benign prostate hyperplasia treatments.

The global benign prostatic hyperplasia therapeutics market is projected to reach $20,096.68 million by 2025 from $10,688.72 million in 2017, at a CAGR of 8.1%.

Benign prostatic hyperplasia (BPH) is a condition in which a man’s prostate grows abnormally large. This condition usually leads to problems starting urination at night, weak urine flow, inability to empty the bladder, and increased frequent urination. BPH therapeutics are drugs that fall into three different classes: alpha blockers, 5-alpha reductase inhibitors, and phosphodiesterase-5 inhibitors. These drugs relieve BHP symptoms by relaxing bladder smooth muscle or reducing abnormal prostate growth. When the bladder muscles relax, the prostate grip in the urethra relaxes and the urine flows more freely. On the other hand, as the size of the prostate shrinks, the pressure that the prostate exerts on the urethra decreases and the urine flows freely.

 Download PDF Report Sample with statistical info @

 Increasing prevalence of benign prostatic hyperplasia, rising global geriatric population, and soaring awareness related to urological disorders and prostate cancer across the world are the factors that drive the global benign prostatic hyperplasia therapeutics market growth. However, higher adoption rate of minimally-invasive surgical therapies instead of BPH therapeutics is expected to impede the market growth. Conversely, high market potential in the untapped emerging economies and presence of several pipeline products are expected to provide many opportunities during the forecast period.

 The utilization rate of alpha blockers is high, owing to high availability of these products characterized by a higher success rate and lesser side effects. However, the 5-alpha reductase inhibitor segment is expected to grow at a high CAGR during the forecast period.

The mono drug therapy segment is the largest segment in the global benign prostatic hyperplasia therapeutics market, expanding at a moderate CAGR during the forecast period. On the other hand, the combination drug therapy segment is anticipated to record a high CAGR during the forecast period.

Key findings of the Benign Prostatic Hyperplasia Therapeutics Market:

The phosphodiesterase-5 inhibitor segment accounted for nearly one-sixth share of the global benign prostatic hyperplasia therapeutics market in 2017.

The mono drug therapy segment is expected to grow at a CAGR of 7.6% from 2018 to 2025.

Europe accounted for around one-third share of the global market in 2017.

LAMEA is expected to provide lucrative market growth opportunities and grow at a CAGR of 9.6% from 2018 to 2025.

 Make an Enquiry for Promocode Of Discounted Price: @

 North America was the leading revenue contributor to the global benign prostatic hyperplasia therapeutics market in 2017, and is expected to dominate the market during the forecast period. This is attributed to the early approval of BPH drugs and high adoption of drugs in this region. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to increase in affordability, surge in healthcare expenditure, and rise in awareness towards safe BPH drugs.

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at

Editor Details

Last Updated: 14-Feb-2020